Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

Author: AndreattaKristen, ChengAndrew, CreticosCatherine, CrofootGordon, CustodioJoseph, DaarEric S, DeJesusEdwin, GrahamHiba, KoenigEllen, LiuYa-Pei, MartinHal, MolinaJean-Michel, OguchiGodson, QuirkErin, RockstrohJürgen K, RuanePeter

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Switching virologically suppressed adults with HIV-1 infection from a boosted protease inhibitor therapy to bictegravir, emtricitabine, and tenofovir alafenamide is a safe and effective option that simplifies the regimen and avoids drug interactions.
Paper Details　
Original Abstract of the Article :
Switching from therapy based on a boosted protease inhibitor to bictegravir, emtricitabine, and tenofovir alafenamide could avoid drug interactions and unwanted side-effects in virologically suppressed adults with HIV-1 infection, while maintaining a high barrier to resistance and providing a simpli...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3018(18)30091-2

データ提供：米国国立医学図書館（NLM）

Switching HIV-1 Regimens: A Journey to Simplified and Effective Treatment

HIV-1 infection requires lifelong treatment to manage the virus and maintain patient health. This study examines the feasibility and effectiveness of switching virologically suppressed patients from boosted protease inhibitor-based regimens to a fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide. The authors aim to assess the safety and efficacy of this switch, exploring its potential to simplify treatment regimens and improve patient adherence.

A Simplified and Tolerable Approach to HIV-1 Treatment

The study's findings suggest that switching to a fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide is a safe and effective option for virologically suppressed patients. This regimen offers a simplified once-daily, single-tablet approach, potentially improving patient adherence and reducing the risk of drug interactions and side effects. The study provides valuable insights into the potential benefits of streamlining treatment regimens for HIV-1 patients.

Finding Easier Paths in HIV-1 Management

This research, like a camel discovering a new and more efficient route through the desert, highlights the potential of simplifying treatment regimens for HIV-1 patients. The development of new drug combinations, like finding a hidden oasis, offers a more convenient and tolerable approach to managing this complex condition. By exploring new pathways, we can enhance the lives of individuals living with HIV-1, providing them with greater hope and well-being.

Dr.Camel's Conclusion

HIV-1 treatment, like a long and arduous journey through a vast desert, requires careful navigation. This study, like finding a shortcut through a labyrinthine landscape, offers a more simplified and effective approach to managing this condition. The discovery of new and more convenient treatment options, like finding a cool spring in a parched desert, offers hope and resilience for individuals living with HIV-1.

Date :
  1. Date Completed 2019-01-30
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

29925490

DOI: Digital Object Identifier

10.1016/S2352-3018(18)30091-2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.